Objective: Insulin-like growth factor binding protein-3 (IGFBP-3) inhibits cell growth. Previous reports have suggested the existence of plasma membrane IGFBP-3 receptors that could mediate direct, IGFindependent effects. Thus far, however, the only well-de®ned putative IGFBP-3 receptor is the type V transforming growth factor-b (TGF-b) receptor, a membrane glycoprotein that mediates TGF-binduced growth inhibition in selected cells. The aim of the study was to test whether IGFBP-3 and TGF-b exert short-term effects in an osteosarcoma cell line that produces no IGF but contains type 1 IGF receptors.
Introduction
Increased levels of insulin-like growth factor (IGF-I) have been associated with breast, prostate and colon cancer growth. IGF-I stimulates growth of a variety of human malignant cells in tissue culture, including breast cancer, prostate carcinoma, and osteosarcoma cells. It is a mitogen for several osteosarcoma cell lines, such as MG-63 (1, 2), Saos-2 (3±5) and OHS-4 (6), and inhibits apoptosis (4) . Type 1 IGF (and insulin) receptors function as tyrosine kinases and signal through these receptors to trigger mitogenic and antiapoptotic pathways. Treatment of Saos-2 cells with aIR-3, a blocking monoclonal antibody against the type 1 IGF receptor, or with an antisense oligonucleotide to the type 1 IGF receptor decreased [ 3 H]thymidine incorporation and cell proliferation, suggesting that signaling via this receptor was necessary for growth and survival of these cells in vitro (7) . IGF binding protein-3 (IGFBP-3), the main GH-dependent IGFBP in adult human serum, blocks IGF-stimulated thymidine incorporation into human ®broblasts (8) and Saos-2 cells (3, 5) in a dose-dependent manner. It induces apoptosis in MCF7 breast cancer cells when tested in the presence of 0.5% FCS over a period of 72 h (9) . Recent studies have indicated that IGFBP-3 may directly inhibit DNA synthesis and promote apoptosis in Hs578T cells, a human breast cancer cell line (10, 11) and in PC-3 human prostate carcinoma cells (12) . IGFBP-3 has, therefore, been suggested to bind to speci®c IGFBP-3 receptors (13) . However, these receptors have not yet been cloned, their signaling pathway has remained elusive, and short-term biological effects have not been clearly documented. In Hs578T breast cancer cells, IGFBP-3 binding was found to correlate with its ability to inhibit growth, and IGF-I (which, by itself, did not stimulate DNA synthesis in this particular cell line) decreased cell surface binding of IGFBP-3 and prevented IGFBP-3-induced growth inhibition (10) . In PC-3 prostate carcinoma cells, IGFBP-3-induced apoptosis was reversed by IGF-I but not by an IGF analog that does not bind IGFBP-3, again suggesting that growth inhibition and apoptosis were caused by IGFBP-3 and not by IGF-I±IGFBP-3 complexes. Moreover, IGFBP-3 has been reported to mediate effects of TGF-b on apoptosis in this cell line (12) . IGFBP-3 has also been shown to predispose Hs578T breast cancer cells to ceramide-induced apoptosis in an IGF-independent manner (11, 14) . Transfection of the human IGFBP-3 gene into murine ®broblasts inhibited cellular proliferation (15) , and inhibited growth of ®broblast cell lines derived from IGF-I receptor-knockout embryonic mice, animals which are not viable after birth (16) . The latter cells exhibit low growth rates, and their apoptosis is enhanced when rhIGFBP-3 is added to the culture medium (12) . Most studies used longterm incubations (24 h and more) to show potentially IGF-I-independent effects of (intact) IGFBP-3, and/or they used genetically manipulated cells, such as IGF-Iunresponsive, type 1 IGF receptor-de®cient cells, i.e. cells that exhibit rather unusual features. In human cancer, however, absence of p53 may be much more common than absence of type 1 IGF receptors. Most of these experimental systems are also complicated by the fact that IGFs and IGFBPs may be locally produced and processed. Therefore, we looked at whether IGFBP-3 and TGF-b affect growth and apoptosis in short-term experiments independently of type 1 IGF (or insulin) receptor signaling in an IGF-responsive cell line that produces no detectable amounts of IGF-I and IGF-II. (IGFBP-3 CHO ), nonglycosylated rhIGFBP-3 expressed in Escherichia coli (IGFBP-3 E. coli ) and rabbit antihuman IGFBP-3 antiserum were kindly provided by Dr A Sommer, Celtrix, Santa Clara, CA, USA. rh transforming growth factor (TGF-b 2 ) was from R&D Systems, Abingdon, UK. Fatty acid-free bovine serum albumin (BSA) was from Sigma (St Louis, MO, USA).
Materials and methods

Cells and peptides
Cell culture
Cells were passaged in Falcon tissue culture¯asks in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with gentamicin (50 mg/ml), glutamine (2 mmol/l) and 10% FCS at 37 8C in an atmosphere of 5% CO 2 in air. Cell cultures between passages 10 and 40 were used. Cells grown to con¯uence were detached from the dishes with 0.25% trypsin and replated either in Falcon six multiwell tissue culture plates (9.6 cm 2 surface area) at a density of 2 Â 10 5 cells per well or in 24 multiwell (2 cm 2 surface area) dishes at a density of 4 Â 10 4 cells per well and grown for 3 days in 5% FCScontaining medium, rinsed with serum-free medium, and incubated for 4 or 18 h in serum-free Ham's F12 medium containing 2 mmol/l glutamine, 50 mg/ml gentamicin and 1 g/l BSA.
Proliferation assay
Thymidine incorporation into DNA After 3 days of growth, the con¯uent cultures were washed in serum-free Ham's F12 medium and incubated in 1 ml serum-free F12 medium supplemented with 2 mmol/l glutamine, 50 mg/ml gentamicin, 1 g/l BSA and test agents for 18 h, pulsed with methyl-[ 3 H]thymidine (Amersham, 85 Ci/mmol; 1 mCi per dish) and further incubated for 3 h at 37 8C. They were then rinsed with ice-cold PBS, and DNA was precipitated with 10% trichloroacetic acid. Incorporated radioactivity was measured in a liquid scintillation counter.
DNA fragmentation assay
Photometric enzyme-immunoassay for determination of cytoplasmic histone-associated DNA fragments An ELISA kit (Cell Death Detection ELISA PLUS from Boehringer Mannheim) was used to measure cytosolic oligonucleosome-bound DNA. The test allows quantitative determination of histone-associated DNA fragments (mono-and oligonucleosomes) and is based on a sandwich-enzyme immunoassay which detects enrichment of mono-and oligonucleosomes in the cytoplasmic fraction of cell lysates by monoclonal antibodies directed against DNA and histones. Processing and analysis of cell culture media Ligand and immunoblot analysis of IGFBPs Conditioned media were collected after 4 and 18 h, centrifuged at 250 g for 10 min, and the supernatants were stored at 220 8C.
125 I-IGF-II ligand blot and IGFBP-3 immunoblot analysis were performed to screen for the production of IGFBPs and to check for the recovery of added rhIGFBP-3. Unprocessed media aliquots were used to check for the recovery of rhIGFBP-3, whereas media were concentrated prior to analysis for detection of secreted IGFBPs. To this end, 10 6 cells were plated in 55 cm 2 dishes in serumcontaining medium as described above, rinsed with serum-free medium and kept for 18 h in 10 ml serumfree Ham's F12 medium containing 1 g/l BSA. Conditioned media were collected, dialyzed against 0.1 mol/l ammonium bicarbonate, lyophilized and dissolved in 200 ml of distilled water. Aliquots (15 ml) were electrophoresed on 15% SDS polyacrylamide gels under non-reducing conditions (except 14 C-labeled molecular weight markers; Rainbow marker, Amersham, UK) and transferred to nitrocellulose membranes. The air-dried ®lters were washed in Tris-buffered saline (TBS; 0.15 mol/l NaCl and 0.01 mol/l Tris, pH 4), containing 0.1% Tween 20 and then incubated with 125 I-labeled IGF-II (4 Â 10 6 cXpXmX per plastic bag) for 6 h at room temperature. After washing with TBS containing 0.1% Tween 20, the ®lters were exposed for 1 day at 280 8C to an X-ray ®lm (Kodak X-OMAT AR) in cassettes equipped with intensifying screens as described (18) . For immunoblot analysis, 30 ml media aliquots were loaded per lane and electrophoresed under reducing conditions. The air-dried ®lters were washed in TBS, pH 7.6, containing 0.1% Tween 20. The ®rst antibody (anti-IGFBP-3) was used at a dilution of 1:1000, the second (anti-rabbit, horseradish peroxidase-conjugated, from Anawa, Wangen, Switzerland) at a dilution of 1:500. Bands were detected by enhanced chemiluminescence with RPN 2106 following the prescription of the supplier (Amersham, UK) as described (4), and their relative intensities were evaluated by densitometry (GS-700, BioRad, Glattbrugg, Switzerland).
Statistical analysis
The results are presented as means^S.E.M.s. The difference between means was evaluated by the Wilcoxon rank order test. A probability level of a random difference of P , 0X05 is considered statistically signi®cant.
Results
Effects of IGF-I and IGF-II
DNA synthesis IGF-I and IGF-II stimulate [ 3 H]thymidine incorporation into DNA of Saos-2/B-10 cells (Fig. 1A) . Both peptides are effective at low concentrations. At 0.3 nmol/l, IGF-I was more effective than IGF-II P , 0X01Y and maximal stimulation was observed at 1 nmol/l IGF-I or at 3 nmol/l IGF-II. IGF-I was two to three times more potent than IGF-II and equally potent as [QAYL]-IGF-I (not shown). To achieve maximal stimulation of [ 3 H]thymidine incorporation into DNA of Saos-2/B-10 cells by insulin, 100 nmol/l was required (not shown).
Apoptosis Microscopic examination of the cell cultures showed that a large number of cells detached from the dishes after serum withdrawal, i.e. during the test period. Less cells detached when they were kept in medium supplemented with IGF-I or IGF-II. Therefore, we analyzed DNA extracted from detached cells for fragmentation. As assessed by gel electrophoreses after 4 and 18 h, DNA was fragmented to a larger extent in control cells, whereas IGF-I and IGF-II prevented DNA fragmentation (not shown).
Since analysis of extracted DNA by gel electrophoresis does not allow us to reliably distinguish apoptosis from necrosis, enrichment of oligonucleosomes in the detached and adherent cells was monitored by using monoclonal antibodies directed against DNA and histones (4). The cell layer lysates were analyzed after 4 h of exposure of the cells to test medium. The data, expressed as absorbance A 405 nm 2 A 490 nm Y show that IGF-I and IGF-II are potent inhibitors of apoptosis (Fig. 1B) . As described for thymidine incorporation into DNA, there is a clear dose±response relationship; IGF-II was less potent than IGF-I by a factor of about 5.
I-IGF-I binding
125 I-IGF-I binding studies showed that ,20% of the added counts was bound. Over 97% of the bound 125 I-IGF-I could be displaced by 1 mmol/l cold IGF-I, i.e. non-speci®c binding was less than 3% of the total binding. Half-maximal displacement was observed at 0.4 nmol/l IGF-I ( (Table 1a) .
[QAYL]-IGF-I is an IGF analog that binds normally to type 1 IGF receptors but has a 600-fold reduced af®nity for IGFBP-3 (19) .
TGF-b 2 was tested under the same conditions, at concentrations up to 0.2 (Table 1b) (Table 1b) .
at a concentration of 10 nmol/l had no effect on DNA degradation as assessed by DNA gel electrophoresis after 4 or 18 h in serum-free test medium (not shown) and no signi®cant effect on apoptosis unless 1 nmol/l IGF-I or 5% FCS were present ( Table 2 ). The data summarized in Table 2 also show that IGFBP-3 had no signi®cant effects by itself (in the absence IGF-I) and no effect when cells were kept in the presence of 100 nmol/l insulin or 1 nmol/l [QAYL]-IGF-I. IGFBP-3
E. coli at a concentration of 10 nmol/l completely blocked the effects of 1 nmol/l IGF-I, but only partially those of 5% FCS (Table 2a) . Identical results were obtained when 10 nmol/l (glycosylated) IGFBP-3 CHO (not shown) were used instead of (non-glycosylated) IGFBP-3 E. coli . TGF-b 2 at a concentration of 0.1 nmol/l had no effect on DNA degradation after 18 h of incubation (not shown) and it had no effect on apoptosis after 4 h of incubation (not shown).
Processing, production and recovery of endogenous and added IGFBP-3 Added rhIGFBP-3 can be recovered from the medium after 18 h of incubation, E. coli ) is found in medium from cells treated with IGF-I than in medium from control-treated cells (Fig. 3A) . IGFBPs produced by the cells were only detectable when the media were concentrated (Fig. 3B) . The ligand blot then showed several IGFBPs apart from the exogenous rhIGFBP-3, including the 45/42 kDa doublet (which is also increased in response to IGF-I as compared with the control) characteristic for IGFBP-3, as also observed in adult human serum (Fig. 3A and B) .
By Western blot analysis using speci®c polyclonal IGFBP-3 antibodies and chemiluminescence, as little as ,1 ng of IGFBP-3 could be detected. Added rhIGFBP-3 CHO could be almost completely recovered after 18 h of incubation, indicating a long half-life. By contrast, IGFBP-3 E. coli was less well recovered (Fig. 4) , probably due to partial losses by rapid adherence to plastic and/ or absorption or (slow) processing by cells, as assessed 
Discussion
Cell characteristics
The primary goal of the present study was to characterize medium-and short-term effects of IGFBP-3 in human Saos-2 cells on DNA synthesis and apoptosis, and to look for potential actions of TGF-b in this cell line. Saos-2 cells, a human osteogenic osteosarcoma cell line, express high alkaline phosphatase activity in a constitutive manner and produce low amounts of collagenous matrix (20, 21) . As compared with non-transformed osteoblasts, both p53 alleles are deleted in Saos-2 cells (5). The p53 tumor-suppressor gene is the most commonly mutated (or deleted) gene in human cancer. p53 transfected into Saos-2 cells decreases type 1 IGF receptor expression by repressing the IGF receptor promoter activity (22, 23) . p53 overexpression was also found to induce IGFBP-3 in colon carcinoma cells (5) . Both ®ndings are consistent with the observation that Saos-2/B-10 cells express high type 1 IGF receptor levels and only small amounts of IGFBP-3 (4). Since wild-type, hyperphosphorylated p53 functions as a brake, the IGF system in p53-de®cient cells participates in enhancing progression through the cell cycle. Moreover, p53-de®cient cells display a poor cell cycle control and poor cell cycle arrest upon serum withdrawal, which may predispose them to undergo apoptosis (see below).
The high number of IGF-I receptors (,100 000/cell) in Saos-2/B-10 cells and the fact that these cells do not express IGF-I and IGF-II (4, 24) may well explain why they are exquisitely sensitive to IGF-I (K d for IGF-I binding and action ,0.3 nM; Figs 1 and 2 ), why they E. coli in the absence and presence of 1 nmol/l rhIGF-I. Comparison with normal human serum (2 ml; lane S). Cells were grown on 10 cm diameter dishes as described in Materials and methods. In (A), 20 ml (i.e. 1/500 of the material) aliquots were analyzed directly (without further processing), whereas in (B), media were dialyzed, lyophilized, reconstituted in 200 ml water and 10 ml (i.e. 1/20 of the material) were loaded per lane. Exposure time for (A) was 3 days and for (B) 1 day. Numbers indicate molecular masses of the markers. coli and rhIGFBP-3 CHO . Cells were grown as described in Materials and methods and exposed to serum-free test medium containing rhIGFBP-3 as indicated. Aliquots (30 ml) were analyzed directly (without further processing), i.e. the lanes loaded with 30 ml of 1 nmol/l of IGFBP-3 contain ,1 ng IGFBP-3. Numbers on the left side indicate molecular masses of the markers. On top, the letter`b' designates before (time point: 0 h) and the letter`a' after (time point: 18 h) incubation with cells. The letter`C' denotes control (no IGF-I),`I' denotes IGF-I, and`Q' denotes [QAYL]-IGF-I.
critically depend on the addition of IGF-I or serum for survival and why the addition of IGFBP-3 in the presence of IGF-I potently abolishes the effects of the latter, most likely by IGF sequestration (4) . As shown by the two dose±response curves in Fig. 1A and B, Saos-2 cells were even approximately threefold more sensitive to IGF-I in terms of inhibition of apoptosis than with regard to stimulation of DNA synthesis. The potencies measured during short-time experiments, e.g. stimulation of phosphate and glucose uptake and glycogen synthesis (3) and inhibition of apoptosis (as shown in this study), may more closely re¯ect signaling through the type 1 IGF receptor than the potencies measured during longer-term incubations, e.g. in thymidine incorporation or cell replication studies. In the latter, IGF-II and even insulin and its analogs become relatively more potent as compared with IGF-I, and the dose±response curves are broader and no longer strictly parallel to the IGF-I dose±response curves obtained for short-term effects (3, 25 and C Schmid, unpublished observations).
In contrast to many reports using other cell types, neither toxic agents nor prolonged incubation times are required for Saos-2 cells to demonstrate an antiapoptotic effect of IGF-I. IGF-I at a concentration of 1 nmol/l is at least as effective as 5% FCS in blocking apoptosis within 4 h (Table 2a) . These ®ndings as well as those presented in Tables 1 and 2 are in line with the observation that signaling through the type 1 IGF receptor is critical for both proliferation and survival of Saos-2 cells (7).
Effects of IGFBP-3
IGFBP-3 has been reported to exert short-term inhibitory and longer-term potentiating effects on IGF-Istimulated DNA synthesis in human (8) and on aminoisobutyric acid uptake in bovine ®broblasts (26) . We had previously found that intact but not truncated IGFBP-3 blocked IGF-I-stimulated DNA synthesis in Saos-2/B-10 and rat osteoblastic cells (3) . We now investigated the effects of IGFBP-3 on apoptosis in addition to those on DNA synthesis. Although we found speci®c 125 I-IGFBP-3 CHO binding to Saos-2 cell layers (not shown), neither DNA synthesis nor apoptosis were affected by IGFBP-3 in the absence of IGF-I or in the presence of [QAYL]-IGF-I which barely binds IGFBP-3. Thus, IGFBP-3 per se has no effect in shortterm (less than 24 h) studies with Saos-2/B-10 cells (Tables 1 and 2 ). These results are in agreement with the observation of Nickerson et al. (9) that IGFBP-3, even over longer term (3 days), overcomes the antiapoptotic effect of IGF-I in MCF-7 breast cancer cells, but not that of long R 3 IGF-I, which has a low af®nity for IGFBP-3. These latter as well as our ®ndings are at variance with the report that IGFBP-3 interacts with type 1 IGF receptors in Chinese hamster lung ®broblasts (CCL39) and thereby inhibits cell growth (27) . The identi®cation of IGFBP-3 as a p53-inducible gene (5) and the ®nding that IGFBP-3 can increase apoptosis have led to the proposal that IGFBP-3 may serve a protective role against cancer cell growth (28), and that part of the IGFBP-3 effects are IGF-independent and mediated by speci®c cell surface IGFBP-3 receptors (10±16, 28). So far, however, the latter have not been chemically identi®ed or cloned. Our data provide evidence at least against direct short-term effects of exogenous IGFBP-3 and thus against speci®c IGFBP-3 cell surface receptors in osteosarcoma cells. They are rather compatible with the well-established notion that IGFBP-3 acts by sequestering IGFs.
In order to test whether the lack of IGFBP-3 effects in the absence of IGF-I was due to IGFBP-3 degradation we checked whether this was the case. However, we found little degradation of IGFBP-3 E. coli (fragments were detectable by immunoblot only after prolonged exposure, not shown), and degradation of IGFBP-3 CHO was not detectable. It has been reported that IGF-I regulates IGFBP-3 in ®broblasts by a non-receptormediated mechanism (29, 30) , a ®nding also reported for human breast cancer cells (31) . Indeed, IGF-I stimulated IGFBP-3 production also in Saos-2/B-10 cells. But again, our observation that IGF-I-stimulated IGFBP-3 production is suppressed by rhIGFBP-3 E. coli (Fig. 3B ) may well be explained by sequestration of the added IGF-I. This is also in line with the data presented in Tables 1 and 2 , which show that IGFBP-3 acts in Saos-2 cells not by itself, but by sequestering IGF. IGFBP-3 E. coli and IGFBP-3 CHO have equal IGF binding properties and, therefore, act identically on IGF-I sequestration despite marked differences in half-life and adsorption characteristics. IGFBP-3 E. coli is more rapidly adsorbed to plastic surfaces than IGFBP-3 CHO , as also observed by Conover (32) .
Effects of TGF-b
Leal et al. recently reported that among several IGFBP-3 binding sites found on extracellular matrix and cell surface structures, the type V TGF-b receptor was the putative IGFBP-3 receptor (33). We, therefore, examined whether TGF-b 2 affected DNA synthesis in Saos-2 cells. Previous studies had indicated that TGF-b 1 and TGF-b 2 inhibit growth with similar potencies and that the type V TGF-b receptor is speci®c for TGF-b 1 and TGF-b 2 binding (34). This 400 kDa membrane glycoprotein mediates TGF-b-induced growth inhibition in mink lung epithelial cells.
125 I-IGFBP-3 E. coli binds to the type V TGF-b receptor with an apparent K d of 6 nmol/l (33) . The same authors also found that several epithelial tumor cell lines, such as human breast cancer MCF-7, HepG2 hepatoma and colorectal carcinoma RII37 and HCT116 cells, lack the type V TGF-b receptor (33, 34) , and that growth of these cells is not decreased by TGF-b. It was, therefore, suggested that lack of the type V TGF-b receptor contributes to an escape from growth inhibition. In Saos-2/B-10 cells, TGF-b 2 does not inhibit DNA synthesis (Table 1b) .
On the other hand, IGFBP-3 has been implicated as a mediator of the actions of TGF-b and p53 (5, 35) , particularly because antisense deoxynucleotide to IGFBP-3 decreased growth inhibition induced by TGF-b 2 in human breast cancer cells (35) and because TGF-b stimulated the expression of IGFBP-3 in ®broblasts (36) and in breast and prostate cancer cells (12, 35) . We have also found that 0.1 nmol/l TGF-b 2 is a potent stimulator of IGFBP-3 expression (as assessed by IGFBP-3 mRNA expression and accumulation of intact immunoreactive IGFBP-3 in the medium) in normal human ®broblasts under conditions where it did not affect IGFBP-3 production in Saos-2/B-10 cells (C Schmid, unpublished observations). TGF-b 2 strongly induces IGFBP-3 production and inhibits proliferation of normal prostatic stromal cells, but much less in cells from benign prostatic hyperplasia (37) . IGFBP-3 does not per se inhibit growth of rat osteoblasts (38) and of Saos-2 cells (this study) but does so only by sequestering locally released or externally provided IGF. Our data are, therefore, fully compatible with the speculation put forward by Leal et al. (33) that locally released IGFBP-3 may cause growth inhibition by sequestering IGFs from binding to type 1 IGF receptors in IGF-responsive cells, although they do not exclude the possibility that IGFBP-3 elicits a growth-inhibitory response mediated by the type V TGF-b receptor.
We conclude that both IGFBP-3 and TGF-b do not exert growth-inhibitory effects in Saos-2/B-10 cells, whereas type 1 IGF (and possibly insulin) receptors and their ligands (IGFs, insulin and their analogs) are critical for both growth and survival. There is no increased apoptosis and growth inhibition in response to IGFBP-3, strongly arguing against the existence of speci®c IGFBP-3 cell surface receptors. In the presence of IGF, sequestration of the latter appears to be the major mechanism of IGFBP-3 action on apoptosis and cell growth.
